

          1. Viral pneumonia with other viruses besides 2019-nCoV.

          2. Patients are not suitable for immunoglobulin therapy.

          3. Participation in other studies.

          4. Other circumstances in which the investigator determined that the patient is not
             suitable for the clinical trial.
      